LMNL
Income statement / Annual
Last year (2022), Liminal BioSciences Inc.'s total revenue was $401.00 K,
a decrease of 37.64% from the previous year.
In 2022, Liminal BioSciences Inc.'s net income was -$28.92 M.
See Liminal BioSciences Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$401.00 K |
$643.00 K |
$3.32 M |
$4.90 M |
$47.37 M |
$39.12 M |
$16.39 M |
$24.53 M |
$23.01 M |
$20.64 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$2.03 M
|
$2.76 M
|
$38.00 M
|
$10.15 M
|
$6.76 M
|
$8.22 M
|
$7.02 M
|
$6.59 M
|
| Gross Profit |
$401.00 K
|
$643.00 K
|
$1.28 M
|
$2.14 M
|
$9.37 M
|
$28.97 M
|
$9.63 M
|
$16.32 M
|
$16.00 M
|
$14.05 M
|
| Gross Profit Ratio |
1
|
1
|
0.39
|
0.44
|
0.2
|
0.74
|
0.59
|
0.66
|
0.7
|
0.68
|
| Research and Development Expenses |
$15.30 M
|
$18.35 M
|
$56.83 M
|
$75.11 M
|
$91.67 M
|
$100.39 M
|
$88.08 M
|
$50.25 M
|
$35.20 M
|
$18.56 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.87 M
|
$31.93 M
|
$38.55 M
|
$45.28 M
|
$31.53 M
|
$31.44 M
|
$29.30 M
|
$16.58 M
|
$12.91 M
|
$8.58 M
|
| Other Expenses |
-$212.00 K
|
$75.00 K
|
$79.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$33.16 M
|
$50.28 M
|
$95.38 M
|
$120.40 M
|
$123.20 M
|
$152.32 M
|
$117.38 M
|
$66.83 M
|
$48.11 M
|
$27.14 M
|
| Cost And Expenses |
$33.16 M
|
$50.28 M
|
$97.41 M
|
$123.16 M
|
$161.20 M
|
$162.47 M
|
$124.14 M
|
$75.04 M
|
$55.12 M
|
$33.74 M
|
| Interest Income |
$0.00
|
$0.00
|
$451.00 K
|
$0.00
|
$307.00 K
|
$313.00 K
|
$363.00 K
|
$374.00 K
|
$310.00 K
|
$42.00 K
|
| Interest Expense |
$1.08 M
|
$6.33 M
|
$8.72 M
|
$14.06 M
|
$22.37 M
|
$8.28 M
|
$4.89 M
|
$3.23 M
|
$3.07 M
|
$1.85 M
|
| Depreciation & Amortization |
$1.12 M
|
$4.34 M
|
$8.45 M
|
$9.91 M
|
$5.46 M
|
$4.58 M
|
$3.25 M
|
$2.44 M
|
$1.69 M
|
$869.00 K
|
| EBITDA |
-$31.86 M |
-$45.21 M |
-$105.17 M |
-$200.72 M |
-$108.08 M |
-$118.47 M |
-$104.13 M |
-$47.70 M |
$4.27 M |
-$9.23 M |
| EBITDA Ratio |
-79.44
|
-70.32
|
-31.71
|
-40.93
|
-2.28
|
-3.03
|
-6.35
|
-1.94
|
0.19
|
-0.45
|
| Operating Income Ratio |
-82.23
|
-77.07
|
-28.42
|
-42.95
|
-2.4
|
-3.15
|
-6.55
|
-2.04
|
0.11
|
-0.49
|
| Total Other Income/Expenses Net |
-$525.00 K
|
$118.00 K
|
-$28.07 M
|
-$237.00 K
|
-$144.37 M
|
-$11.74 M
|
-$9.51 M
|
-$11.41 M
|
$31.63 M
|
-$7.16 M
|
| Income Before Tax |
-$29.44 M
|
-$44.95 M
|
-$122.34 M
|
-$234.46 M
|
-$257.92 M
|
-$134.79 M
|
-$116.89 M
|
-$61.92 M
|
-$480.00 K
|
-$17.27 M
|
| Income Before Tax Ratio |
-73.42
|
-69.9
|
-36.88
|
-47.81
|
-5.44
|
-3.45
|
-7.13
|
-2.52
|
-0.02
|
-0.84
|
| Income Tax Expense |
-$525.00 K
|
$118.00 K
|
-$201.00 K
|
-$237.00 K
|
-$20.02 M
|
-$14.75 M
|
-$6.22 M
|
-$5.14 M
|
-$3.06 M
|
$131.00 K
|
| Net Income |
-$28.92 M
|
-$45.06 M
|
-$122.14 M
|
-$234.22 M
|
-$195.37 M
|
-$109.73 M
|
-$100.81 M
|
-$50.96 M
|
$5.94 M
|
-$16.49 M
|
| Net Income Ratio |
-72.11
|
-70.08
|
-36.82
|
-47.76
|
-4.12
|
-2.81
|
-6.15
|
-2.08
|
0.26
|
-0.8
|
| EPS |
-341.8 |
-532.66 |
-1443.7 |
-2768.61 |
-2359.49 |
-1378.53 |
-1684.64 |
-892.74 |
100 |
-339.91 |
| EPS Diluted |
-9.32 |
-14.94 |
-49.97 |
-145.82 |
-2359.49 |
-1378.53 |
-1684.64 |
-892.74 |
100 |
-339.91 |
| Weighted Average Shares Out |
$84.60 K
|
$84.60 K
|
$84.60 K
|
$84.60 K
|
$82.80 K
|
$79.60 K
|
$59.84 K
|
$57.08 K
|
$53.04 K
|
$48.51 K
|
| Weighted Average Shares Out Diluted |
$3.10 M
|
$3.02 M
|
$2.44 M
|
$1.61 M
|
$82.80 K
|
$79.60 K
|
$59.84 K
|
$57.08 K
|
$57.81 K
|
$48.51 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
